- Home
- THCH vs WHWK Comparison
THCH vs WHWK Comparison
Compare THCH & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THCH
- WHWK
- Stock Information
- Founded
- THCH 2018
- WHWK 2007
- Country
- THCH China
- WHWK United States
- Employees
- THCH N/A
- WHWK N/A
- Industry
- THCH Blank Checks
- WHWK Biotechnology: Pharmaceutical Preparations
- Sector
- THCH Finance
- WHWK Health Care
- Exchange
- THCH Nasdaq
- WHWK Nasdaq
- Market Cap
- THCH 84.2M
- WHWK 90.0M
- IPO Year
- THCH N/A
- WHWK N/A
- Fundamental
- Price
- THCH $2.62
- WHWK $2.19
- Analyst Decision
- THCH
- WHWK
- Analyst Count
- THCH 0
- WHWK 0
- Target Price
- THCH N/A
- WHWK N/A
- AVG Volume (30 Days)
- THCH 14.4K
- WHWK 133.0K
- Earning Date
- THCH 11-11-2025
- WHWK 11-15-2025
- Dividend Yield
- THCH N/A
- WHWK N/A
- EPS Growth
- THCH N/A
- WHWK N/A
- EPS
- THCH N/A
- WHWK N/A
- Revenue
- THCH $187,316,342.00
- WHWK $21,596,000.00
- Revenue This Year
- THCH N/A
- WHWK N/A
- Revenue Next Year
- THCH N/A
- WHWK N/A
- P/E Ratio
- THCH N/A
- WHWK N/A
- Revenue Growth
- THCH N/A
- WHWK N/A
- 52 Week Low
- THCH $1.95
- WHWK $1.39
- 52 Week High
- THCH $5.15
- WHWK $3.81
- Technical
- Relative Strength Index (RSI)
- THCH 49.97
- WHWK 78.67
- Support Level
- THCH $2.50
- WHWK $1.85
- Resistance Level
- THCH $2.74
- WHWK $1.97
- Average True Range (ATR)
- THCH 0.09
- WHWK 0.10
- MACD
- THCH 0.01
- WHWK 0.03
- Stochastic Oscillator
- THCH 48.00
- WHWK 88.64
About THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.